Strategic Intellegence Software
for clarity
INTO COMPLEX CLAIMS
AMS solves affordability of care issues with a targeted focus on Specialty Pharmaceuticals, Catastrophic Diagnoses and Medical Implants.
AMS’ Predict Suite combines technology, clinical expertise, financial insight and data science into an easy to deploy, subscription-based service that brings strategic intelligence and risk mitigation to high cost claims issues.
Simply put: Knowledge is Power.
The Predict Suite At Work
AMS delivers crucial Cost and Clinical Insight into:
- Specialty Drugs
- Medical Implants
- Catastrophic Diagnoses
Specialty Drugs
In 2018, the $318 billion in specialty medicines represented 41% of developed market spending, up from $172 billion in 2013. In 2017, 90% of the prescription drug volume in the U.S. were generic and accounted for just 23% of total drug costs. Yet specialty drugs composed just 1.9% of total prescription volume but accounted for 37% of spend.
Prescription benefits prices don’t have to be a hard pill to swallow.
Medical Implants
The global market for Medical Device Technologies reached nearly $521.2 billion in 2017 and should reach $674.5 billion by 2022, at a compound annual groth rate (CAGR) of 5.3% for the period of 2017-2022.
The US spends more than $150 billion – 6% of total medical costs – a year on medical devices.
Catastrophic Diagnoses
Catastrophic diagnoses which result in multi-million-dollar claims affect 6% of health plan members but make up 47% of the claims dollar spent. In the last five to seven years, a cataclysmic shift in the cost of care has resulted in a huge increase in both severoty and frequency of catastrophic claims, mostly due to specialty drugs, transplants, and neonatal care.
What You Can Expect
Increased Productivity
Transparency
Medical Appropriateness
Payment Integrity
Risk Recognition
Improved Loss Ratios
Knowledge is power.
Partner with AMS and gain the industry cost transparency you've been waiting for.